Luca Salassa
banner
lsalassa.bsky.social
Luca Salassa
@lsalassa.bsky.social
Canavese (TO, Italy), Chemist, Metals, Photochem, Bioinorgchem, Flavins, 🦓, 🏀, 🐲
Reposted by Luca Salassa
🚨 PhD Opportunity @UMU! Join a 4-year funded FPI project on light-activated metallodrugs for cancer therapy. Start: Jan 2026 | Deadline: Oct 15, 2025 📧 Contact: jruiz@um.es 📎 PDF attached – official link coming soon! #PhDOffer #CancerResearch #FPIContract #UMU #ChemistryJobs
September 23, 2025 at 5:37 AM
Reposted by Luca Salassa
📢Our latest issue is online!

🔓Check out the #OpenAccess paper behind the cover by @giampaolobarone.bsky.social, Ana Silva & co @bip-unipa.bsky.social & University of Porto looking at sulphur-containing pyrrolidine-fused chlorins for potential photodynamic applications

pubs.rsc.org/en/content/a...
September 17, 2025 at 1:00 PM
Reposted by Luca Salassa
#CiQUSintheMedia 🗞 | Un sistema molecular con potencial para recoñecer dianas do ADN asociadas ao cancro: A investigación de Miguel Vázquez, destacada nel Correo Gallego

www.elcorreogallego.es/santiago/202...

#FondosEuropeos #RedeCIGUS
El CiQUS desarrolla una molécula con potencial para aplicarse en nuevas terapias contra el cáncer
El trabajo fue liderado por el catedrático de la USC Miguel Vázquez López
www.elcorreogallego.es
August 20, 2025 at 4:14 PM
Reposted by Luca Salassa
This is the complete speaker line-up for POLYMAT Spotlight 2026!
29 June – 2 July, 2026 hashtag#POLYMATsptl
More details at: polymat-spotlight.eu
September 16, 2025 at 7:31 AM
Reposted by Luca Salassa
🚀 New from @MICLABatUNIPI
Our latest paper in @daltontrans.rsc.org explores Pt(IV) prodrugs functionalized with α-TOS and nanoparticle encapsulation to boost cisplatin/oxaliplatin therapies.

Read here 👉 pubs.rsc.org/en/content/a...
Redefining platinum(IV) chemotherapy: α-tocopherol succinate functionalization and nanoparticle encapsulation to improve cisplatin- and oxaliplatin-based therapies
Platinum(iv) prodrugs offer a promising strategy to overcome the limitations of cisplatin and oxaliplatin, including systemic toxicity and acquired resistance. In this study, two novel α-tocopherol su...
pubs.rsc.org
August 18, 2025 at 8:51 PM
Marta's first PhD article in Chem Commun!
CAGE ILs/DESs and Pt anticancer agents. In collaboration with Francesca Re, University of Milano Bicocca.

pubs.rsc.org/en/Content/A...
Choline–geranate (CAGE) ionic liquids potentiate the anticancer activity of platinum-based drugs
The influence of choline and geranic acid-based ionic liquids (CAGE ILs) on the anticancer activity of selected Pt(ii) and Pt(iv) complexes was investigated. All complexes exhibited appreciable solubi...
pubs.rsc.org
July 16, 2025 at 7:44 AM
Reposted by Luca Salassa
Big news! 🚀
Our new paper is out in JACS!
👉 pubs.acs.org/doi/10.1021/...
“Unlocking a Biological Interface of Chiral Supramolecular Helical Polymers”
#DNAjunction #SupramolecularChem #ChemSky
@acs.org @pubs.acs.org @jacs.acspublications.org
Unlocking a Biological Interface of Chiral Supramolecular Helical Polymers
Here we report a C3-symmetric metal-binding tripeptide, BTMA-1, that self-assembles in water into either a chiral supramolecular helical polymer or a discrete CoII peptide helicate, depending on metal coordination. The CoII peptide helicate exhibits high affinity and selectivity toward DNA three-way junctions (3WJ), a class of noncanonical DNA structures with emerging biological relevance. Importantly, we demonstrate that the recognition process can be triggered dynamically by adding CoII ions to a dispersion of the supramolecular polymer, which acts as an inert precursor reservoir in physiological media. In this way, our strategy shows that chiral supramolecular helical polymers can form temporarily inactive aggregates that release discrete helicates for biomolecular recognition, such as 3WJ binding, upon metal ion coordination. Overall, this mechanism reveals a previously unexplored capability of this class of materials and offers a new approach for the design of responsive supramolecular systems for nucleic acid recognition and anticancer therapy.
pubs.acs.org
June 11, 2025 at 2:54 PM
Reposted by Luca Salassa
Bihar, ez ezazu galdu Jesus Ugaldearen hitzaldia

2025 ekainak 10 • 19:00
Ernest Lluch K.E. Donostia-San Sebastián

@dipcehu.bsky.social

www.donostiakultura.eus/eu/agenda/id...
Ideien kimika. Unibertso kimikoaren azken muga
Kimika Fakultatearen 50. urteurrena dela eta, 50 urte kimika zabaltzen zikloa antolatu da, bertan Kimika Fakultateko kideek Fakultatean garatzen diren hainbat gairen inguruan arituko dira, publiko oro
www.donostiakultura.eus
June 9, 2025 at 6:21 PM
Reposted by Luca Salassa
🎉 Honored to share that I’ve been appointed as a new board member of @aebin25.bsky.social at #BioCiudadReal25.

Grateful for the trust and excited to contribute to the growth of our vibrant community of spanish bioinorganic chemists.

#AEBIN #BioinorgChem #ChemSky
June 4, 2025 at 7:45 AM
Reposted by Luca Salassa
The 50th anniversary of the Faculty of Chemistry at the University of the Basque Country (UPV/EHU) will be celebrated at the Donostia is Science international conference that is starting today.

ℹ️https://labur.eus/wmv2fxbu

#UIK #OnTheSideOfKnowledge
May 28, 2025 at 9:45 AM
Catalytic Glutathione Oxidation and Platinum(IV) Prodrug Activation via a Ruthenium-Flavin Catalyst
Cyclopentadienyl (Cp) Ru(IV) quinoline complexes are known for their role in bioorthogonal catalysis within cellular environments, where they use endogenous GSH to deprotect profluorescent and prodrug substrates. However, their reactivity toward GSH and potential for redox-mediated therapies remain underexplored. This study presents RuQ-TARF, a Cp-Ru(IV) complex with a quinoline ligand linked to 2′,3′,4′,5′-tetraacetylriboflavin (TARF) as a redox-active moiety. Its catalytic activity in oxidizing GSH and activating a Pt(IV) prodrug of oxaliplatin was investigated. RuQ-TARF catalyzes the oxidation of GSH to GSSG, improving electron transfer compared to RuQ, its flavin-free analogue. LC–MS analysis showed that activating the Pt(IV) prodrug with GSH produces multinuclear Pt(II)-GS species. RuQ-TARF was additionally evaluated during coincubation with GSH and NADH under blue light, where NADH enabled faster activation of the prodrug, producing oxaliplatin as confirmed by 1H and 195Pt NMR. Cyclic voltammetry showed that linking TARF to RuQ improves the reversibility of redox processes, enhancing catalytic performance and supporting its use in combined GSH oxidation and prodrug activation strategies.
pubs.acs.org
April 24, 2025 at 6:25 PM
Reposted by Luca Salassa
Come join us for our biannual meeting in Ciudad Real!

More info here:
www.biociudadreal.es
January 16, 2025 at 10:52 AM
Reposted by Luca Salassa
Hello bsky! My lab at CiQUS develops metallopeptide tools for nucleic acid junctions and G-quadruplexes. We are particularly interested in peptide helicates and DNA-3WJ. Please follow us for more news about our research #DNA #RNA #metallopeptides #chemicalbiology #supramolecularchemistry
November 15, 2024 at 2:42 PM